Search

everythinglearnresearchcommunity

for

Search:↓

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.

TGF-β inhibitors may help treat liver fibrosis by targeting various pathways.

Radiation treatment causes skin fibrosis by increasing certain fibroblast subpopulations, but using a c-Jun inhibitor or fat grafting can reduce this effect.

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

Gefitinib can cause slower, finer, brittle, and curly scalp hair.

Blocking a certain signal in the gp130 receptor can improve tissue healing and lessen osteoarthritis symptoms.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Ac-GFFY-IGF peptide is a promising, safe, and effective treatment for hair loss, better than current options.

Alternating treatment with two drugs could help cells in a rapid aging disease.

Targeting amphiregulin may improve treatment for fibrosis and cancer.

Gefitinib can cause rare scarring hair loss.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.

CGF therapy may effectively treat psoriasis by reducing inflammation.

Targeting amphiregulin may improve treatment for fibrotic diseases and cancer.

Fibroblast Growth Factor-9 (FGF-9) can help improve heart function in diabetic mice after a heart attack by reducing inflammation and harmful changes to the heart's structure.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

Filgotinib completely reversed hair loss in a patient with rheumatoid arthritis and alopecia universalis.

FGF18 helps hair follicles resist radiation by stopping hair growth cycles.

EGFR inhibitors can cause skin issues, but managing them is important for treatment success.

Blocking IL-8 can reduce skin rashes from cancer treatment.

Reducing gefitinib dosage improved hair loss, but scarring remained.

JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.

Curcumin, EGCG, barringtozenol, and finasteride are effective VEGFR inhibitors.

Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.

The document concludes that doctors should monitor children's brain development when treating hemangiomas with interferon alfa and consider stopping the treatment if problems arise, while also exploring drugs that might counteract side effects.

Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.